September 16th 2025
The FDA has granted fast track designation to the investigational drug CRB-701 for recurrent or metastatic head and neck squamous cell carcinoma.
September 15th 2025
September 15th 2025
September 15th 2025
September 14th 2025
September 12th 2025
September 11th 2025
September 10th 2025
September 10th 2025
July 13th 2025